Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation

• Tipo: Artigo em Revista Científica Internacional
• Data: 2016

Autores

Doktorovová, S (Autor) Outra; Kova¿evi¿, AB (Autor) Outra; Garcia, ML (Autor) Outra; Souto, EB (Autor) Outra

Revista

Título: European Journal of Pharmaceutics and Biopharmaceutics

Vol. 108

Páginas: 235-252

ISSN: 0939-6411

Editora: Elsevier

Indexação

ISI Web of Knowledge - 46 Citações

Scopus - 124 Citações

Outras Informações

ID Authenticus: P-00Y-1F0

DOI: 10.1016/j.ejpb.2016.08.001

Abstract (EN): Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) were designed as exceptionally safe colloidal carriers for the delivery of poorly soluble drugs. SLN/NLC have the particularity of being composed of excipientsalready approved for use in medicines for human use, which offers a great advantage over any other nanoparticulate system developed from novel materials. Despite this fact, any use of excipients in new route of administration or in new dosage form requires evidence of safety. After 25 years of research on SLN and NLC, enough evidence on their preclinical safety has been published. In the present work, published data on in vitro and in vivo compatibility of SLN/NLC have been surveyed, in order to provide evidence of high biocompatibility distinguished by intended administration route. We also identified critical factors and possible weak points in SLN/NLC formulations, such as the effect of surfactants on the cell viability in vitro, which should be considered for further development. © 2016 Elsevier B.V.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 18